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Background: According to the American College of Cardiology/American Heart Association/European Society
of Cardiology guidelines, the choice of aspirin or warfarin to prevent thromboembolic events (TEs) in patients
with nonrheumatic atrial fibrillation (AF) should be based on the CHADS2 score. The purpose of this study
was to determine the predictors of warfarin use in patients with AF at low (CHADS2 = 0) or intermediate
(CHADS2 = 1) risk for TEs.
Hypothesis:Warfarin use is low in intermediate- and low-risk patients.
Methods: Clinical characteristics of 3086 consecutive patients (mean age, 70 ± 13 years) with nonrheumatic
AF from an academicmultispecialty practice were determined between 2006 and 2008 through individual chart
review. Patients were identified based on an inpatient or outpatient encounter, in which a billing diagnosis
code of AF or atrial flutter (AFl) was recorded. The decision for anticoagulation was at the discretion of the
primary care physician or cardiologist. No intervention to guide anticoagulant therapy was made.
Results: Warfarin was prescribed in 180/497 low-risk patients (36%), and in 646/938 intermediate-risk
patients (69%). Among high-risk patients (CHADS2 ≥ 2), warfarin was used in 792/968 patients (82%)
with a CHADS2 = 2, in 343/410 patients (84%) with a CHADS2 = 3, and in 225/273 patients (82%) with
a CHADS2 ≥ 4. On multivariate analysis, independent predictors of warfarin use in low-risk patients were
nonparoxysmal AF (odds ratio [OR]: 5.02, P< 0.0001) and age between 65 and 74 years (OR: 2.21, P< 0.0001).
Among intermediate-risk patients, congestive heart failure (OR: 7.34, P< 0.0001), nonparoxysmal AF (OR:
4.04, P< 0.0001), coronary artery disease (OR: 2.53, P< 0.0001), age between 65 and 74 years (OR: 1.68,
P = 0.002), and female gender (OR: 1.69, P = 0.002) were independent predictors of warfarin use. Lack of
warfarin use (OR: 4.9, P< 0.001) and female gender (OR: 2.0, P = 0.03) were associated with a higher risk
of TEs in intermediate-risk patients. None of the CHADS2 parameters was predictive of TEs. Warfarin was not
associated with reduction in TEs in low-risk patients. Warfarin use did not have a significant effect on bleeding.
Conclusions: Although either aspirin or warfarin is recommended to prevent TEs in patients with AF at
intermediate risk for TEs, warfarin is preferred in the majority of patients in general practice. Lack of warfarin
use is associated with a higher risk of TEs in intermediate-risk patients with AF. The adoption of new oral
anticoagulants that have lower risk ofmajor hemorrhage thanwarfarin for low- or intermediate-risk AF patients
remains to be determined.
Introduction
Atrial fibrillation (AF) is associated with a risk of
thromboembolic events (TEs) and is a major cause
of stroke.1 Randomized controlled trials have demon-
strated that warfarin significantly reduces the risk of
TEs in high-risk patients2–4 but increases the risk
The authors have no funding, financial relationships, or conflicts
of interest to disclose.
of major bleeding.5 The American College of Cardiol-
ogy/American Heart Association/European Society of Car-
diology (ACC/AHA/ESC) guidelines on the management
of AF recommend treatment with aspirin or warfarin based
on the CHADS2 risk scoring system.1 Aspirin is recom-
mended for patients with a CHADS2 score of 0, and warfarin
is recommended for high-risk patients with CHADS2 ≥ 2.
Patients with a CHADS2 score of 1 may be treated with
either aspirin or warfarin. The purpose of this study was
to determine patterns and predictors of warfarin use in
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low- and intermediate-risk patients with AF and their associ-
ation with major thromboembolic and bleeding events. We




The subjects of this study were 3086 consecutive patients
identified from clinical encounters from July 1, 2006 through
December 31, 2008 from the University of Michigan Health
System’s electronic medical records. Patients were selected
based on an inpatient or outpatient encounter in which
a billing diagnosis code of AF or atrial flutter (AFl)
was recorded (ICD-9-CM 427.31 or 427.32). Patients were
also included in the study if they were followed in a
dedicated anticoagulation clinic for a diagnosis of AF or
AFl. Patients were excluded for rheumatic heart disease
or complex congenital heart disease, another indication
for anticoagulant therapy such as mechanical valves or
venous thromboembolic disease, or cardiac transplantation
or left ventricular assist device implantation. Warfarin use
among patients who had undergone a catheter ablation
procedure for AF was censored for the 3 months following
the procedure. Clinical characteristics of the patients are
shown in Table 1.
Data Collection and Analysis
This study protocol was approved by the University of
Michigan Institutional Review Board. Data on clinical
characteristics and comorbidities were collected through
individual chart reviews using electronic medical records.
Table 1. Clinical Characteristics
On Warfarin (%) No Warfarin (%)
Age, mean, years 71.61 ± 11.97 65.86 ± 14.37
Male 1352/1947 (69.4) 595/1947 (30.6)
Female 837/1139 (73.5) 302/1139 (26.5)
History of TEs 387/451 (85.8) 64/451 (14.2)
Hypertension 1560/2032 (76.8) 472/2032 (23.2)
Diabetes mellitus 524/647 (81.0) 123/647 (19.0)
Congestive heart failure 272/311 (87.5) 39/311 (12.5)
Age ≥75 years 998/1253 (79.6) 255/1253 (20.4)
Age 65–74, years 613/832 (73.7) 219/832 (26.3)
Coronary artery disease 603/728 (82.8) 125/728 (17.2)
CHADS2 = 0 180/497 (36.2) 317/497 (63.8)
CHADS2 = 1 648/938 (69.1) 290/938 (30.9)
CHADS2 = 2 792/968 (81.8) 176/968 (18.2)
CHADS2 = 3 344/410 (83.9) 66/410 (16.1)
CHADS2 ≥ 4 225/273 (82.4) 48/273 (17.6)
Abbreviations: TEs, thromboembolic events.
CHADS2 score was determined as described previously: 1
point each for congestive heart failure (CHF), hypertension,
diabetes mellitus, or age ≥75 years, and 2 points for
a history of transient ischemic attacks (TIA) or stroke
(CVA).6 In addition, as described in the ACC/AHA/ESC
guidelines, minor risk factors including coronary artery
disease (CAD), female gender, and age 65 to 74 years were
noted for each patient.1 Adverse events were reported by
physicians and collected from individual chart review. All
TEs, primarily CVA or TIA, and any bleeding event such
as gastrointestinal, intracranial bleeding, or other minor
bleeding were noted. Self-terminating episodes of AF within
7 days were considered paroxysmal, whereas all other types
were categorized as nonparoxysmal AF.1
Statistical Analysis
Data are shown as mean ± standard deviation. Continuous
variables were compared using the Student t test, and cate-
gorical variables were compared with the χ2 test. Statistical
analyses were performed using SPSS for Windows statistical
software version 17.0 (SPSS Inc., Chicago, IL). Multivariate
logistic regression analysis was performed to identify predic-
tors of warfarin use. Both forward and backward likelihood
ratio methods were used to evaluate agreement between the
models. P < 0.05 was considered statistically significant.
Results
CHADS2 Score and Warfarin Use
Warfarin was prescribed in 180/497 patients (36%) with
a CHADS2 score of 0, and 646/938 patients (69%) with
a CHADS2 score of 1. Among high-risk patients, 792/968
(82%) with a CHADS2 score of 2, 343/410 (84%) with a
CHADS2 score of 3, and 225/273 patients (82%) with a
CHADS2 score ≥4 were receiving warfarin (Figure 1).
Predictors of Warfarin Use in Low-Risk Patients
(CHADS2 =0)
Among low-risk patients with a CHADS2 score of 0, non-
paroxysmal AF (61% vs 24%, P < 0.001) and age between
65 to 74 years (50% vs 30%, P < 0.001) were univariate
predictors of warfarin use. On multivariate analysis, non-
paroxysmal AF (odds ratio [OR]: 4.95, ± 95% confidence
interval [CI]: 3.23–7.60, P < 0.001) and age 65 to 74 years
(OR: 2.22, ± 95% CI: 1.43–3.43, P < 0.001) remained signif-
icant predictors of warfarin use.
Predictors of Warfarin Use in Intermediate-Risk Patients
(CHADS2 = 1)
On univariate analysis, patients with nonparoxysmal AF
were more likely to receive warfarin than patients with
paroxysmal AF (84% vs 58%, P < 0.001). Patients with CHF
were more likely to be prescribed warfarin than patients
with any of the other CHADS2 risk factors. In addition,
patients with a CHADS2 score of 1 with CAD were more
likely to receive warfarin (82% vs 66%, P < 0.001). There was
a trend for higher warfarin use in women than men (73% vs
67% for men, P = 0.07).
On multivariate analysis, left ventricular (LV) dysfunc-
tion with an ejection fraction ≤0.35 (OR: 6.68, ±95% CI:
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Figure 1. Proportion of patients on warfarin based on the CHADS2 score.
Table 2. Independent Predictors of Warfarin Use in Intermediate Risk
Patients
OR ±95% CI P
Congestive heart failure 6.68 2.79–15.97 <0.0001
Nonparoxysmal AF 4.08 2.94–5.68 <0.0001
Age ≥75 years 1.49 0.97–2.28 0.067
Minor risk factors
Coronary artery disease 2.53 1.55–3.61 <0.0001
Age 65–74 years 1.81 1.31–2.51 <0.0001
Female 1.50 1.09–2.08 0.013
Abbreviations: AF, atrial fibrillation, CI, confidence interval; OR, odds
ratio. Variables included in the model were congestive heart failure,
hypertension, diabetes mellitus, age 65 to 74 years, age >75 years,
race, gender, paroxysmal or nonparoxysmal AF, and coronary artery
disease or peripheral vascular disease.
2.79–15.97, P < 0.0001) and nonparoxysmal AF (OR: 4.09,
±95% CI: 2.94–5.68, P < 0.0001) were independent pre-
dictors of warfarin use in intermediate-risk patients. The
other CHADS2 risk factors did not predict warfarin use,
although there was a trend toward use of warfarin in patients
≥75 years (OR: 1.489, ± 95% CI: 0.97–2.28, P = 0.067).
Patients with a CHADS2 score of 1 who also had 1 of the
minor risk factors, including CAD (OR: 2.53, ±95% CI:
1.63–3.98, P < 0.0001), age 65 to 74 years (OR: 1.68, ±95%
CI: 1.21–2.34, P = 0.002), or female gender (OR: 1.69,
±95% CI: 1.21–2.34, P = 0.002) were more likely to be on
warfarin (Table 2).
Thromboembolic Events
TEs occurred during the study period in 110 patients. There
were 331 patients who had a TE prior to the study period
which is reflected in their CHADS2 score. Among the 110
patients who had a TE during the study period, 75 (68%) were
not receiving warfarin and 35 patients (32%) were receiving
warfarin at the time of the TE. Among the 75 patients who
were not on warfarin at the time of TE, the CHADS2 score
was 0 in 8 patients; 1 in 30 patients, and ≥2 in the remaining
37 patients. Among the 37 patients who were on warfarin,
the CHADS2 score was 0 in 1 patient; 1 in 13 patients; and
≥2 in the remaining 23 patients (P = 0.28)(Figure 2). The
TE event rate per year was 0.9% in patients with a CHADS2
score of 0 and 2.3% in patients with a CHADS2 score of 1
during the 2-year study period.
Predictors of Thromboembolic Events
On univariate analysis, there was no association between
warfarin use and the risk of TEs in patients with a CHADS2
Figure 2. Warfarin use and thromboembolic events. The percentage of
patients within each CHADS2 category who suffered from
thromboembolic events and their anticoagulation status is shown.
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score of 0. However, in patients with a CHADS2 score of 1,
warfarin use was associated with a lower probability of TEs
than aspirin or no specific therapy (2% vs 9%, P < 0.001).
There also was a trend toward higher prevalence of TEs in
women than men (6.1% vs 3.5%, P = 0.06).
On multivariate analysis, warfarin use was not associated
with a lower risk of TEs in patients with a CHADS2
score of 0. Among CHADS2 1 patients, lack of warfarin
use (OR: 4.9, ± 95% CI: 2.56–9.45, P < 0.001) and
female gender (OR: 2.0, ± 95% CI: 1.07–3.71, P = 0.03)
were both independent predictors of TEs; hypertension,
diabetes, or age ≥75 years were not themselves predictors
of TEs.
Bleeding Complications
A bleeding complication occurred in 15 patients (3%) with a
CHADS2 score of 0, and warfarin was subsequently discon-
tinued in 5. In patients with a CHADS2 score of 1, a bleeding
complication was observed in 47 patients (3%), and warfarin
was discontinued in 6. Among high-risk patients with a
CHADS2 score ≥ 2, warfarin had been discontinued in 50
patients (3%) due to a prior bleeding event. Nineteen patients
discontinued warfarin due to prior fall or documented risk




The main findings of this study were: (1) despite
ACC/AHA/ESC guidelines, ∼40% of low-risk CHADS2
0 patients with AF and ∼70% of intermediate-risk CHADS2
1 patients received warfarin; (2) low-risk patients with non-
paroxysmal AF or age 65 to 74 years were more likely
to receive warfarin; (3) among intermediate-risk patients,
history of CHF or nonparoxysmal AF were associated
with a higher probability of warfarin use; (4) the pres-
ence of an additional minor risk factor (female gender,
CAD, or age 65–74 years) independently predicted warfarin
use in intermediate-risk patients, but individual CHADS2
factors alone did not; and (5) warfarin was associated
with a reduction in TEs in intermediate-risk patients
with AF.
These findings suggest that warfarin is overused in
patients at low risk for TEs despite ACC/AHA/ESC
guidelines. However, in intermediate-risk patients, warfarin
appears to be more appropriate than aspirin in preventing
TEs, particularly in the presence of additional minor risk
factors.
Predictors of Warfarin Use
Although the 2006 ACC/AHA/ESC guidelines recommend
risk stratification based on the CHADS2 score, our data sug-
gest that other variables drive the decision to anticoagulate
with warfarin. Specifically, the presence of nonparoxys-
mal AF strongly influences warfarin use among low- and
intermediate-risk patients with AF. Prior studies also demon-
strated the tendency among physicians to prescribe warfarin
based on the presence of nonparoxysmal AF.7,8 However,
current guidelines suggest that the decision to anticoagulate
with warfarin should not be based on whether AF is parox-
ysmal or persistent, because both types of AF are associated
with a similar risk of TEs.
In patients with AF at intermediate risk for TEs, either
aspirin or warfarin can be used based on current guide-
lines. Warfarin was prescribed in 70% of CHADS2 1 patients
in this study. Although there was an interaction between
age and gender(ie, females with AF were older than the
male patients) both female gender and age 65 to 74 years
were independent predictors of warfarin use. Furthermore,
age ≥75 years, a CHADS2 variable, was not an independent
predictor, suggesting that there is a tendency among practi-
tioners to prescribe warfarin earlier than the suggested age
threshold of 75 years.
Our data possibly reflect an implicit adoption of a
CHA2DS2-VASc scoring system because gender, younger
age, and CAD were incorporated into the decision to
prescribe warfarin for many CHADS2 1 and CHADS2
0 patients. CHADS2 0 patients with a CHA2DS2-VASc score
of 1 or 2 might benefit more from warfarin than the
CHADS2 scheme would suggest. Although the CHA2DS2-
VASc scoring system has only been adopted by the ESC
guidelines yet was not addressed in recent updates to
the ACC/AHA guidelines for the management of AF, it
may be that physicians in our center had already trended
toward that model of risk stratification during this study
period.9,10 However, the CHA2DS2-VASc system still does
not account for the tendency to prescribe warfarin for
nonparoxysmal AF.
The 2006 ACC/AHA/ESC guidelines recommend war-
farin in AF patients with LV dysfunction, although LV
dysfunction by itself is not a recognized criterion for
anticoagulation.1 In this study, LV dysfunction was iden-
tified as an independent predictor of warfarin use in patients
with AF.
Thromboembolic Events
Warfarin was associated with a lower risk of TEs in
intermediate-risk CHADS2 1 patients with AF. Our data
confirm findings in other reports that warfarin reduces the
risk of TE in this patient cohort, although the risk of major
bleeding may result in a marginal benefit with warfarin use
for CHADS2 1 patients.11 Among CHADS2 1 patients, the
tendency of physicians in our practice to prescribe warfarin
when minor risk factors were present might also account
for the effectiveness of warfarin in reducing TEs in this
population, a difference that might have been accounted
for if the CHA2DS2-VASc scoring system had been used.
However, new anticoagulants, such as dabigatran, that are
associated with a lower risk of major hemorrhage than
warfarin may be preferable to antiplatelet agents in patients
with a CHADS2 score of 1.12,13
Prior Studies
Several studies have already demonstrated underuse of war-
farin in patients at high risk for stroke.1,14,15 However, there
are few studies on warfarin use in low- and intermediate -risk
patients. Similar to the findings of this study, warfarin was
demonstrated to be beneficial in intermediate-risk patients
in a prior retrospective analysis.16 In that study, warfarin use
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was lower than the present study, whereas the annual TE
event rate was 11%, which is higher than rates listed in other
studies for CHADS2 1 patients. In this study, the annual TE
event rate was consistent with other studies, yet a significant
reduction in TEs was still demonstrated with warfarin.
A recent meta-analysis of warfarin use in patients with
AF that focused on the net clinical benefit by subtracting
the risk of intracranial hemorrhage from the reduced risk
of TEs with warfarin suggested the net effect of warfarin is
pronounced in patients >85 years and who have CHADS2
score ≥4. In patients with a CHADS2 score of 1 there was
marginal potential benefit.11
Limitations
A limitation of this study is that it is subject to all the inherent
limitations of retrospective studies. Adverse events and
comorbidities were identified through physician reporting,
but there was no confirmation of events because there was
no communication with patients or physicians to confirm
events or diagnoses. A second limitation is that time in
therapeutic range with warfarin could not be determined. A
third limitation is the relatively short duration of follow-up,
limiting the ability to accurately assess long-term cumulative
risk of TEs and hemorrhagic events. A fourth limitation is
that antiplatelet agent use could not be accurately captured
within the dataset. A fifth limitation is that this study was
performed at an academic university-based medical center
and may not represent well clinical practices in the general
community.
Conclusion
This study suggests that warfarin is often used in patients
at low risk for TEs without any clear indication and likely
benefit. Despite the abundance of data and guideline rec-
ommendations, nonparoxysmal AF appears to influence the
decision to anticoagulate patients at low and intermediate
risk for TEs. Patients at intermediate risk for TEs appear
to benefit from anticoagulation despite the risk of major
hemorrhage. Given the results of recent trials demonstrat-
ing the superiority of new oral anticoagulants, the use of
these anticoagulants among low- and intermediate-risk AF
patients remains to be seen.
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